ALK inhibitors have proved an efficacious modality for targeted cancer therapy [46] since the launch of crizotinib in 2011 for the clinical treatment of ALK-positive non-small cell lung cancer (NSCLC) [47]. Here, ALK is linked to non-small cell lung carcinoma.